OCA improves event free survival – EASL 2022 – POSTER
Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBALPBC itch & Health Related Quality of Life -EASL 2022 – POSTER
More than just an itch: Impact of cholestatic pruritus in primary biliary cholangitis (PBC) on health-related quality of life (HRQoL) Cholestatic pruritus (particularly severe pruritus) has a significant negative impactPBC prevalence on the rise – EASL 2022 – POSTER
The prevalence of primary biliary cholangitis (PBC) is on the rise: a Canadian population-based study In this well-defined cohort, we reported a significant increase in the prevalence of PBC inExercise improves fatigue in PBC patients – EASL 2022- POSTER
Home-based exercise in patients with refractory fatigue associated primary biliary cholangitis: final results from the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) clinical trial A 12-wk individualized HBEP, incorporating resistance12 Week mind-body intervention for PBC patients – EASL 2022 – POSTER
A randomized control trial evaluating the impact of a web-based mind-body wellness intervention for patients with primary biliary cholangitis This 12-week intervention improved measures of mental wellness and quality of life.
Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population
“Little is known about PBC affecting subjects with heterogeneous genetic backgrounds [4]. Brazil has a population of a highly admixed origin, with varying proportions of Amerindian, African, and European geneticAnxiety & Depression in patients with PBC
“The two most commonly reported symptoms among patients with PBC are fatigue and pruritus which may be debilitating, and negatively impact physical, mental, emotional, and social wellbeing. Intense symptom burden
Combination Therapy works for PBC
Study concludes that triple therapy with UDCA, OCA and fibrates is able to normalise biochemical liver tests and improve pruritus in patients with difficult‐to‐treat PBC. Read full study.
OCA real world experience
Since OCA (Ocaliva) was approved in the US in 2016 and Canada in 2017, there have been several studies to assess its effectiveness in PBC patients around the world. Here